135 related articles for article (PubMed ID: 6774444)
21. Resistance to activated F IX concentrate (FEIBA).
Stenbjerg S; Jorgensen J
Scand J Haematol; 1977 May; 18(5):421-6. PubMed ID: 877518
[TBL] [Abstract][Full Text] [Related]
22. [A case of sigmoid cancer who acquired factor V inhibitor producibility and treated with factor VIII inhibitor bypassing activity preparation FEIBA--with bibliographic review (author's transl)].
Abe T; Kazama M; Itokazu K; Kinoshita T; Ogushi T; Tahara C; Fukui H
Rinsho Ketsueki; 1980 Nov; 21(11):1664-73. PubMed ID: 6782277
[No Abstract] [Full Text] [Related]
23. Remission of acquired factor-VIII-inhibitor-induced bleeding.
Ghosh ML
Acta Haematol; 1980; 64(3):179-80. PubMed ID: 6778052
[No Abstract] [Full Text] [Related]
24. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
[No Abstract] [Full Text] [Related]
25. Current concepts in the management of hemophilia.
Abildgaard CF
Semin Hematol; 1975 Jul; 12(3):223-32. PubMed ID: 1079631
[No Abstract] [Full Text] [Related]
26. Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody.
Blatt PM; White GC; McMillan CW; Webster WP
JAMA; 1984 Jan; 251(1):67. PubMed ID: 6418898
[No Abstract] [Full Text] [Related]
27. Post-partum treatment of a patient with a factor VIII inhibitor.
Files JC; Morrison FS; Halbrook J
N Engl J Med; 1981 Dec; 305(27):1650. PubMed ID: 6796887
[No Abstract] [Full Text] [Related]
28. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ
N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990
[TBL] [Abstract][Full Text] [Related]
29. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
30. [Bilateral prosthesis of the knee in a hemophilia A patient with an inhibitor].
Lauroua P; Barbier F; Dieu P; Dumora D; Moulinier J
Ann Fr Anesth Reanim; 1986; 5(2):154-6. PubMed ID: 3089078
[TBL] [Abstract][Full Text] [Related]
31. New activated factors IX product in haemophilia.
Abonstam A; Aston L; Wassef M; Hamad Z
Lancet; 1980 Dec; 2(8207):1294. PubMed ID: 6108461
[No Abstract] [Full Text] [Related]
32. [Dental care for hemophilic patients. II. Consequences for dental practice].
Ned Tijdschr Tandheelkd; 1982 May; 89(5):200-5. PubMed ID: 6213874
[No Abstract] [Full Text] [Related]
33. Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor.
Lowe GD; Harvie A; Forbes CD; Prentice CR
Br Med J; 1976 Nov; 2(6044):1110-1. PubMed ID: 990791
[No Abstract] [Full Text] [Related]
34. [Substitution therapy with factor 8 and factor IX preparations].
Landbeck G
Hamatol Bluttransfus; 1968; 5():29-42. PubMed ID: 5729465
[No Abstract] [Full Text] [Related]
35. Circulating antibodies in factor VIII deficiency hemophilia: report of case.
Cudzinowski L
ASDC J Dent Child; 1979; 46(1):54-6. PubMed ID: 283081
[No Abstract] [Full Text] [Related]
36. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
Verroust F; Moussard C; Allain JP
Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
[TBL] [Abstract][Full Text] [Related]
37. Evidence that less replacement therapy is required for dental extractions in hemophiliacs.
Steinberg SE; Levin J; Bell WR
Am J Hematol; 1984 Jan; 16(1):1-13. PubMed ID: 6421150
[TBL] [Abstract][Full Text] [Related]
38. Early treatment of hemophilia with minimal doses of factor VIII or factor IX.
Ripa T; Scaraggi FA; Ciavarella N
Blood; 1978 Apr; 51(4):763. PubMed ID: 630121
[No Abstract] [Full Text] [Related]
39. Effect of phospholipid on factor VIII inactivation.
Barrowcliffe TW; Kemball-Cook G; Gray E
Prog Clin Biol Res; 1984; 150():251-63. PubMed ID: 6431431
[No Abstract] [Full Text] [Related]
40. Conjectures on factor VIII bypassing activity.
Aronson DL
Prog Clin Biol Res; 1981; 72():103-21. PubMed ID: 6977778
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
